Flonoltinib - Moligand™, 10 mM in DMSO , CAS No.2387765-27-5

CAS: 2387765-27-5 Cat. No.: F1496031 Formula: C₂₅H₃₄FN₇O Peso molecolare: 467.58

GRADE & PURITY Moligand™, 10 mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Panoramica

Flonoltinib is a potent and orally active dual JAK2/FLT3 inhibitor with IC 50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2 , FLT3 , JAK1 and JAK3 , respectively. Flonoltinib has anti-cancer activity.

Specifications

Specifiche e purezza

Moligand™, 10 mM in DMSO

Condizioni di conservazione di stoccaggio

Store at -80°C

Spedito in

Dry ice packs + Cold packs

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Grado

Moligand™

Nomi e identificatori

Peso molecolare

467.58

Application Protocols

No manufacturer-validated protocols are provided for this item. The following general workflow is commonly used for small-molecule screening compounds:

Stock preparation and plating:

• Warm to room temperature while kept sealed to avoid condensation.
• Dissolve in anhydrous DMSO to a validated concentration (e.g., 10–50 mM). Vortex, sonicate briefly if required, and verify concentration by UV or quantitative NMR if necessary.
• Aliquot into single-use portions in low-bind, amber vials or 96/384-well plates; minimize headspace and freeze at recommended storage temperature.

Assay setup (general):

• Thaw aliquots once; avoid repeated freeze–thaw.
• Dilute into assay buffer to the desired final concentration range, matching vehicle controls.
• For biochemical assays, include detergent (e.g., 0.01–0.05% Tween-20) if aggregation is suspected; confirm activity with orthogonal readouts.
• For cell-based assays, confirm tolerated vehicle % and test for cytotoxicity independently of the primary endpoint.

These steps are provided as general guidance only and are not product-specific validations.

Biological Roles

No biological mechanism, pathway involvement, or target annotations are provided for this item in the product data.

General notes for small-molecule research tools:

• Compounds in discovery libraries are often evaluated for interactions with enzymes, receptors, transporters, or signaling proteins, but activity is highly structure- and context-dependent.
• Without target disclosures, Flonoltinib should be treated as a chemical probe candidate whose biological effects must be established empirically in your assay system.
• When assessing biological roles, implement controls to detect common assay interferences (aggregation, redox cycling, fluorescence quenching, or promiscuous reactivity).
• Establish concentration–response behavior, evaluate selectivity against off-target panels where relevant, and confirm reproducibility across lots/aliquots.

Important: Any biological or pharmacological interpretations should be based on your own data or primary literature specific to this CAS. This product is supplied strictly for research use only.

Buffer Applications

This item is a small-molecule screening compound and is not itself a buffering agent. Therefore, standard buffer system design (e.g., phosphate, HEPES, Tris) is not directly applicable to the compound as a buffer component.

Practical guidance for use of buffers with small molecules:

• Prepare concentrated stocks in an appropriate organic solvent (often DMSO), then dilute into assay buffer while keeping final organic content at a level compatible with the biological system.
• Choose buffers with minimal compound–buffer interactions: HEPES or PBS are common for biochemical assays; avoid buffers that can react with labile moieties (e.g., primary amines with aldehydes).
• Maintain constant ionic strength and pH during titrations to prevent apparent potency shifts due to ionization changes.
• If precipitation occurs upon dilution, add solvent gradually with mixing, reduce compound concentration, or include a minimal percentage of co-solvent (validated for your assay).

For formulation-like needs (e.g., long incubations), assess stability of the compound in the chosen buffer by LC–MS over the experimental timeframe.

Green Alternatives

Because Flonoltinib is a target compound (screening molecule) rather than a solvent or auxiliary reagent, the concept of a greener substitute pertains mainly to handling and vehicle choice rather than replacement of the compound itself.

Greener handling choices (general guidance):

• Prefer water-miscible, lower-toxicity vehicles and minimize organic content in assays (e.g., keep DMSO ≤0.5–1% v/v when possible, and avoid DMF/NMP in biological contexts).
• For preparative dissolution, consider ethanol or 2-propanol as interim wetting agents before final dilution, provided the compound’s stability permits.
• Apply microscale operations (HTE plates, low-dead-volume tips) to reduce chemical use and waste.
• Choose amber vials or light-protective storage to reduce the need for stabilizers or antioxidants, if the compound is light-sensitive (structure-dependent; verify).

Illustrative vehicle comparison (general):

• DMSO (benchmark): broad solvency, good assay tolerance at low %; not readily biodegradable.
• Ethanol: greener, but weaker solvency for very lipophilic compounds and may perturb cells at similar % v/v.
• Acetonitrile: volatile and useful for analytics; less suitable as a biological vehicle.

Select the smallest effective solvent volume and validate stability to minimize waste and re-preparations.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation specifications are provided for this product. It is supplied for research use only and is not intended for human or veterinary use.

Context for researchers (general):

• If evaluating pre-formulation concepts (solubility, stability, permeability) in an R&D setting, ensure that salt form, polymorphism, and residual solvent levels are defined for the specific lot (refer to CoA/Spec Sheet).
• For any exposure-related experiments (in vitro ADME, permeability), prepare high-quality, well-characterized stocks and document vehicle percentages rigorously.
• Do not construe the product name as implying therapeutic claims. Any clinical or GMP-related development requires independently sourced material with appropriate regulatory documentation and quality controls beyond a research grade.

Physical Properties

Item-specific physico-chemical data are not provided in the current listing.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting/boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density/refractive index: Not specified for this item; refer to CoA/Spec Sheet.
• LogP/logD, pKa: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.

General guidance (literature/practice for small-molecule screening compounds):

• Many drug-like solids are prepared and stored as concentrated DMSO stocks (e.g., 10–50 mM) for biochemical/phenotypic assays. Actual solubility and stability, however, depend strongly on structure, salt form, and hydration and must be verified experimentally.
• If hydrophobic, co-solvents such as DMF, NMP, or small percentages of ethanol/PEG-400 in aqueous buffers are sometimes used; if polar/ionizable, aqueous buffers at appropriate pH can improve solubility.
• Always confirm physicochemical parameters via CoA/Spec Sheet or preliminary screening (kinetic solubility, nephelometry, and stability by LC–MS) before large-scale studies.

Quality and Grades

• Grade/Purity: Moligand™ (Aladdin small-molecule/ligand library grade).

What Moligand™ typically signifies (general guidance):

• Designed for discovery workflows (biochemical/biophysical screening, cell-based assays) with emphasis on identity verification and suitability for small-volume dispensing.
• Items are commonly supplied with identity confirmation (e.g., LC–MS/HRMS, HPLC purity, and/or NMR). The exact characterization set, purity threshold, salt form, and counterions are item-specific—please refer to the CoA/Spec Sheet for this catalog number.

Implications for use:

• Library-grade materials are optimized for reproducibility in screening cascades; they are not necessarily optimized for synthetic-scale reagents or GMP applications.
• For analytical applications (e.g., reference standards), confirm that assay-related impurities, residual solvents, water content, and salt form are acceptable for your method validation.
• If low UV background or metal limits are critical, verify specifications explicitly—these attributes are not specified for this item; refer to CoA/Spec Sheet.

Batch documentation:

• Request the CoA for the specific lot to obtain purity, analytical methods, and any stabilizers or formulating excipients used in packaging.

Reaction and Applications

This product is offered as a discrete small molecule for screening and research use rather than as a general-purpose synthetic reagent.

• Not typically applied as a reagent or catalyst in named organic reactions. If you intend to incorporate it into synthetic transformations (e.g., derivatization, prodrug linkage, or immobilization), you will need the structural information and functional-group map from the CoA/Spec Sheet to plan conditions and protections.
• Common research uses (general for library compounds):
  • Biochemical screening (enzyme or binding assays).
  • Biophysical profiling (thermal shift, SPR, DSF) provided solubility and stability support such workflows.
  • Phenotypic/cell-based studies with appropriate vehicle control and concentration–response design.
• Practical tips:
  • Establish a fresh DMSO master stock at validated concentration; avoid repeated freeze–thaw by making single-use aliquots.
  • Confirm chemical and assay stability (t0/t24 LC–MS or HPLC in vehicle and in assay buffer).
  • Evaluate aggregation risk (e.g., detergent-sensitivity, dynamic light scattering) to avoid false positives in biochemical assays.

For any structure-dependent applications (e.g., photoactivity, redox behavior), consult the structure in the CoA/Spec Sheet.

Reaction Conditions

No reaction conditions are specified for this item, and it is not positioned as a reagent or catalyst.

General handling for assay stock preparation (laboratory practice):

• Dissolution: Start with an anhydrous solvent such as DMSO at room temperature, with gentle vortexing or brief sonication.
• Concentration: Prepare a verified master stock (e.g., 10–50 mM), filtered if needed (0.22 µm PTFE/PVDF).
• Dilution: Add stock to aqueous buffers with thorough mixing to avoid local supersaturation; maintain consistent vehicle percentage across controls.
• Stability checks: Run t0/t24 HPLC or LC–MS in both stock and diluted matrices; store working plates at low temperature and minimize light exposure if indicated by structure.

If you intend to use Flonoltinib in a chemical reaction, obtain the structure and consult primary literature for any documented transformations of this scaffold; otherwise, standard “reaction conditions” are not applicable.

Safety and Handling

• GHS classification: Not specified for this item; refer to SDS.
• Signal word / H-statements / Pictograms: Not specified for this item; refer to SDS.

General laboratory safety (professional guidance):

• Handle in a fume hood with appropriate PPE: lab coat, nitrile gloves, safety glasses. Avoid inhalation, ingestion, and skin/eye contact.
• Prevent dust/aerosol formation if supplied as a solid. For DMSO or organic solutions, avoid contact with skin due to potential dermal absorption.
• Use clean, dry tools for aliquoting to minimize cross-contamination and moisture ingress, particularly for low-temperature stored materials.
• Incompatibilities are structure dependent; as a precaution, avoid strong oxidizers, strong acids/bases, and reactive acylating/alkylating agents until compatibility is known.
• First aid (overview; consult SDS): rinse affected skin/eyes with water for ≥15 minutes; seek medical attention if irritation persists. If inhaled, move to fresh air; if ingested, do not induce vomiting—seek medical attention.
• Waste disposal: collect organic solutions and contaminated materials as hazardous chemical waste per institutional and local regulations.

Always defer to the product SDS for authoritative safety information and emergency procedures.

Solvent Selection

Item-specific solubility parameters are not provided. The following are general best practices for small-molecule screening compounds:

• Primary vehicles: DMSO is the default solvent for assay stocks due to broad solvency and biological compatibility at low percentages.
• Secondary/co-solvents: DMF, NMP, ethanol, acetonitrile, or PEG-400 can assist with dissolution when DMSO is insufficient.
• Aqueous use: Prepare concentrated organic stocks, then dilute into assay buffers (e.g., PBS, HEPES) while maintaining final organic content typically ≤1% v/v, as assay tolerance allows.
• pH leverage: If the compound is ionizable (unknown here), adjust buffer pH to favor solubilized form; verify stability versus hydrolysis/oxidation by LC–MS.
• Filtration: Use 0.22 µm PTFE or PVDF filters for organic solutions to remove particulates prior to assays.

Small comparison (general):

• DMSO vs DMF: DMSO is more biocompatible and preferred for HTS; DMF can aid very hydrophobic analytes but is less favored in live-cell systems.
• Acetonitrile vs ethanol: ACN offers low viscosity and volatility for UHPLC compatibility; ethanol is more benign biologically but less powerful as a solvent.

Always verify actual solubility and stability for Flonoltinib using the supplied lot before experimental deployment.

Storage and Reconstitution

• Storage Conditions (item-specific): Store at −80°C.
• Shipping (item-specific): Shipped on dry ice packs + cold packs.

Best practices:

• Upon receipt, promptly transfer to a −80°C freezer. Avoid frost-free appliances that undergo warm cycles.
• Allow containers to equilibrate to room temperature before opening to prevent moisture condensation.
• Prepare single-use aliquots to minimize freeze–thaw cycles; repeated thawing can accelerate degradation even at low temperatures.
• If supplied as a solid: reconstitute in anhydrous solvent (commonly DMSO) to prepare a master stock at your required concentration. Verify complete dissolution and record solvent lot and concentration.
• If supplied as a solution: confirm solvent composition and concentration on the CoA/label; store tightly capped and protected from light if indicated.
• Stability and retest date: Not specified for this item; refer to CoA/Spec Sheet.

Disposal: Follow institutional hazardous waste procedures for organic solutions and contaminated consumables.

Research use only.

Structure and Identity

SKU: F1496031
Product Name: Flonoltinib
CAS: 2387765-27-5

• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• Synonyms: Not specified for this item; refer to CoA/Spec Sheet.

Structural description (general):

• Flonoltinib is listed as a discrete small-molecule entity within a screening/compound library (Moligand). Without an available structure, functional groups, ring systems, stereocenters, and other features cannot be detailed here.
• If your workflow depends on substructure alerts (PAINS, reactive functionality) or physicochemical filters (e.g., Lipinski, Veber), please request or consult the structure file (SDF/SMILES) in the CoA/Spec Sheet before use.

Identification guidance:

• Use the CAS number above for cross-referencing supplier catalogs and bibliographic databases.
• For analytical authentication (HPLC/LC–MS, HRMS, NMR), obtain the reference spectrum and acceptance criteria from the product CoA.

Synthetic Utility

Flonoltinib is offered as a finished small molecule for screening and is not typically used as a synthetic building block.

• Without disclosed structure, retrosynthetic analysis or functional-group transformations cannot be recommended.
• If you plan to derivatize (e.g., biotinylation, photo-crosslinking handles, fluorophore tagging), obtain the structural formula and identify modifiable positions that do not abrogate the compound’s putative activity.
• For analytical chemistry purposes (e.g., internal standardization), confirm stability under chromatographic conditions and ionization modes (ESI/APCI) by pilot LC–MS runs.
• Solid-phase immobilization or linker attachment strategies are strictly structure-dependent; consult the CoA/Spec Sheet and consider computational docking/SAR to prioritize attachment points.

In short, treat this item primarily as a test article rather than as a general reagent unless your lab has the structural dossier and validated derivatization routes.

Target Specificity

Target, mechanism, and selectivity data are not provided for this item.

• No antigen/epitope/clone/isotype information applies (this product is not an antibody or protein).
• For small molecules, “target specificity” must be established empirically. Consider screening against broad panels or orthogonal assays to characterize on- and off-target profiles.

Item-specific target details: Not specified for this item; refer to CoA/Spec Sheet and any associated technical notes.